Ravindre Panchia to Treatment Outcome
This is a "connection" page, showing publications Ravindre Panchia has written about Treatment Outcome.
Connection Strength
0,268
-
Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075. Int J Infect Dis. 2021 Mar; 104:465-470.
Score: 0,037
-
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020 Sep; 24(9):2520-2531.
Score: 0,036
-
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
Score: 0,032
-
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 11; 18(11):1241-1250.
Score: 0,032
-
Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One. 2017; 12(5):e0177281.
Score: 0,029
-
Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017 05; 18(3):100-109.
Score: 0,029
-
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2017 Jan 01; 74(1):112-116.
Score: 0,028
-
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013 Nov 09; 382(9904):1555-63.
Score: 0,023
-
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
Score: 0,022